| P50 | author | Olivier Hérault | Q60142572 |
| | Herve Avet-Loiseau | Q61112732 |
| | Charles Dumontet | Q68319804 |
| P2093 | author name string | J L Harousseau | |
| | R Bataille | |
| | R Garand | |
| | P Moreau | |
| | C Mathiot | |
| | L Voillat | |
| | N Robillard | |
| | N Varoqueaux | |
| | IFM group | |
| | F Garnache | |
| | L Benboukher | |
| P2860 | cites work | Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 |
| | Many and multiple myeloma(s) | Q35545068 |
| | Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity | Q40259744 |
| | CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. | Q52018083 |
| | CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications | Q56991197 |
| | The (11;14)(q13;q32) Translocation in Multiple Myeloma | Q58050931 |
| | Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells | Q67534782 |
| | t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma | Q79087985 |
| | Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma | Q79901816 |
| P433 | issue | 4 | |
| P921 | main subject | rituximab | Q412323 |
| | multiple myeloma | Q467635 |
| P304 | page(s) | 835-836 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Rituximab in CD20 positive multiple myeloma | |
| P478 | volume | 21 | |